Departments of Radiation Oncology and Respirology, London Health Sciences Centre, London, Ontario, Canada.
Departments of Radiation Oncology and Pulmonology, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan, Amsterdam, The Netherlands.
J Thorac Oncol. 2020 Jun;15(6):902-913. doi: 10.1016/j.jtho.2020.02.005. Epub 2020 Feb 24.
Interstitial lung disease (ILD) is a term used to describe a heterogeneous group of lung disorders with characteristic clinical and imaging features. Patients with ILD are at an increased risk of developing NSCLC, which is frequently medically comorbid, often precluding operative management. In this scenario, radiotherapy (RT) is generally recommended; however, ILD is known to increase the risk of RT-related toxicity. Recommendations for treatment with appropriately individualized risks and benefits are thus dependent on integration of patient-, ILD-, and cancer-specific factors. We aim to provide an overview of ILD for the thoracic oncologist, an assessment of risk of thoracic RT in patients with ILD, and evidence-based recommendations for treatment in a variety of clinical scenarios.
间质性肺疾病 (ILD) 是一组具有特征性临床和影像学特征的异质性肺疾病的统称。ILD 患者发生 NSCLC 的风险增加，常合并医学疾病，常使手术治疗变得不可行。在此情况下，通常推荐进行放射治疗 (RT)；然而，ILD 会增加与 RT 相关毒性的风险。因此，基于个体化风险和获益的治疗推荐取决于患者、ILD 和癌症特征的综合评估。我们旨在为胸科肿瘤医生提供ILD 概述，评估ILD 患者接受胸部 RT 的风险，并为各种临床情况下的治疗提供基于循证的建议。
